Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
Revvity expands genomic sequencing services with Genomics England in landmark newborn screening programme
, /in E-News /by panglobalRevvity, Inc. has significantly expanded its collaboration with Genomics England to provide comprehensive genomic screening services for newborns in England. The new agreement builds upon an existing partnership by adding DNA sequencing services to Revvity’s current DNA extraction capabilities.
Bio-Rad secures IVDR certification for molecular quality controls portfolio
, /in E-News /by panglobalBio-Rad Laboratories has achieved a significant regulatory milestone with EU Quality Management Systems certification under the In Vitro Diagnostic Regulation (IVDR), enabling CE marking for 40 infectious disease molecular quality control products from their Exact Diagnostics brand.
FairJourney Biologics establishes Supervisory Board to accelerate antibody discovery innovation
, /in E-News /by panglobalFairJourney Biologics S.A., a global leader in antibody discovery and development based in Porto, Portugal, has announced the formation of a new Supervisory Board aimed at enhancing the company’s strategic positioning and accelerating innovation in antibody research. The board, comprising distinguished industry veterans with extensive expertise in biopharmaceutical development, will focus on defining key growth […]
DayOne Accelerator relaunches to bridge healthtech innovation gap with pharma industry
, /in E-News /by panglobalThe equity-free accelerator programme, based in Basel’s life sciences hub, aims to address the 80% failure rate of healthtech startups by providing direct access to pharmaceutical expertise and resources.
German clinical diagnostics leader partners with US genomics innovator to advance cancer testing
, /in E-News /by panglobalCancer diagnostics in Germany is set to enter a new phase as Labor Dr. Wisplinghoff collaborates with US-based Genomic Testing Cooperative to implement advanced molecular testing capabilities, with RNA analysis at the forefront of this precision medicine initiative.
Navigo Proteins and SCK CEN join forces to advance targeted radiotheranostics
, /in E-News /by panglobalGerman biotechnology company Navigo Proteins has established a strategic research collaboration with SCK CEN, the Belgian Nuclear Research Centre, to accelerate development of targeted radiotheranostics. The partnership aims to combine Navigo’s expertise in precision carrier molecules with SCK CEN’s capabilities in radioisotope production and preclinical testing.
Wiley expands forensic capabilities with updated designer drugs database
, /in E-News, Therapeutic Drug Monitoring /by panglobalWiley has announced the release of its 2025 edition of the Mass Spectra of Designer Drugs database, a critical resource expanding forensic laboratories’ capabilities in the identification of illicit substances. The updated database represents a substantial advancement in analytical tools available to forensic scientists combating the proliferation of novel psychoactive substances.
Alarming rise in child deaths from antimicrobial resistance
, /in E-News /by panglobalNew research reveals over 3 million children died globally from AMR-related infections in 2022, with particular concerns about increasing use of critical antibiotic classes.
IL-6 biomarker breakthrough for early sepsis detection
Sepsis, /in E-News, Molecular Diagnostics /by panglobalNew research identifies interleukin-6 as a superior diagnostic biomarker for sepsis in high-risk populations including neonates, children, and pregnant women.
Pfizer halts development of oral GLP-1 agonist danuglipron
, /in E-News /by panglobalSafety concerns prompt Pfizer to terminate development of once-daily oral GLP-1 receptor agonist for weight management, despite promising pharmacokinetic data from recent dose-optimisation studies.